A case of tumour necrosis factor-α inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab-Reference-Cited by-同舟云学术

A case of tumour necrosis factor-α inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab

Published:2014-11-03 Issue:6 Volume:171 Page:1546-1549
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Jayasekera P.¹,Parslew R.¹,Al-Sharqi A.¹

Affiliation:

1. Department of Dermatology; Royal Liverpool and Broadgreen Hospitals NHS Trust; Liverpool U.K

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.13146/fullpdf

Reference15 articles.

1. National Institute for Health and Care Excellence Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198) http://www.nice.org.uk/guidance/TA247

2. Psoriasis triggered by infliximab in a patient with Behçet's disease;Kawazoe;Jpn J Ophthalmol,2013

3. Psoriasis and pustular dermatitis triggered by TNF-α in patients with rheumatologic conditions;Gannes;Arch Dermatol,2007

4. Incidence of new-onset and flare of pre-existing psoriasis during rituximab;Thomas;J Rheumatol,2012

5. Development of psoriasis after B cell depletion with rituximab;Dass;Arthritis Rheum,2007

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab‐induced psoriasis in a patient with pemphigus vulgaris: A case report and literature review;Clinical Case Reports;2024-03

2. Inpatient Evaluation and Management of Generalized Pustular Dermatoses;Current Dermatology Reports;2023-12-11

3. Tocilizumab and its usage for skin diseases;Italian Journal of Dermatology and Venereology;2022-02

4. Relevance of Inflammatory Cytokine mRNA Expression of Tumour Necrosis Factor- Alpha (TNF α), Interleukin 17A (IL 17A) and Interleukin 6 (IL 6) in Indian Patients with Psoriasis;Indian Dermatology Online Journal;2022

5. Application of IL-6 antagonists in autoimmune disorders;Translational Autoimmunity;2022